|

This
Phase III clinical trial is for patients with non-operable, progressive
and/or recurrent glioblastoma multiforme. To find out if you might
be eligible to participate in this study, please review the inclusion
and exclusion criteria outlined below. However, please contact a
trial centre for more information about the trial and eligibility
requirements, and discuss with your doctor before beginning any
treatment.
INCLUSION CRITERIA INCLUDE (BUT ARE NOT
LIMITED TO):
• Male or female at least 18 years of age
• Diagnosed GBM
• Progressive and/or recurrent GBM after conventional therapy
• Patient is not considered a candidate for surgery
• Karnofsky Performance
Score 70-100
• Tumour characteristic must be:
• Unifocal
• Unilateral
• Lesion diameter equal
to or greater than 1.0 cm and equal to or less than 4.0 cm
EXCLUSION CRITERIA INCLUDE (BUT ARE NOT
LIMITED TO):
• Chemotherapy within 30 days prior to study entry, or nitrosoureas
or
Mitomycin-C therapy
within 42 days prior to study entry
• Radiotherapy or stereotactic
(gamma knife) radiosurgery within 90 days prior to
study entry
• Tumour surgery, tumour
debulking or other neurosurgery procedure within 30 days prior
to study entry
|